Ann: Presentation of BIT225-009 HIV-1 Phase 2 Data, page-586

@Davisite you are singing the old song again. You are assuming the primary was failed.
read this part of aware query response from the company

Primary Objectives:
• Determine the efficacy of 12 weeks of BIT225 treatment in HIV‐1 infected subjects receiving
cART: Atripla® [Tenofovir disoproxil fumarate (TDF) / emtricitabine (FTC) / efavirenz (EFV)] by
measuring plasma viral load decay and modelling HIV‐1 decay.
This primary objective was designed to investigate a virologic effect. This virologic approach involved
measuring plasma viral load decay i.e. blood levels of HIV‐1. Two different methods were used to investigate
this objective. The first was measurement of cell‐free virus in the blood (known as plasma viral load). The
second was measurement of cell‐associated virus in specific cell populations isolated from the blood.
As disclosed in the announcement of 28 September 2018, no differences were noted in the levels of cell‐free
virus (plasma viral load) in the blood. This result was expected because of the effectiveness of current ART,
which all trial participants were taking. Plasma viral load was rapidly reduced to undetectable levels in all
subjects.
The second component of this virological analysis, i.e. measurement of cell‐associated virus in specific cell
populations, is ongoing. This is a very sensitive method compared to measurement of free virus in the blood
and may provide additional virologic information on relative differences in HIV‐1 decay in different blood cell
populations.​

so now where does it say the primary was failed. Please note BIT225 wasn't trailed on its own ,it was used with ART Rx.